Filing Flows › Neogenomics (NEO) › Q2 2025
Neogenomics (NEO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 29, 2025
Neogenomics (NEO) reported revenue of $181M for the second quarter 2025 (Q2 2025), +10% from a year earlier and +8% from the quarter before. Operating margin was -26.3%, net loss $45.1M (24.9% of revenue).
Neogenomics, Q2 2025: revenue $181M (+10% year over year), operating margin -26.3%, net loss $45.1M, operating cash flow $20.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $181M | +8% | +10% |
| Operating profit | −$47.6M | — | — |
| Net earnings | −$45.1M | — | — |
| Operating cash flow | $20.3M | — | +46% |
| Free cash flow | $14.0M | — | 17× |
What changed
Revenue was $181.3M in Q2 2025, up 10% year over year and up 8% from the previous quarter. Client direct billing was the largest line at 72% of revenue. Client direct billing added $12.9M year over year (up 11%), 76% of the total change. Self-pay declined 87%.
Gross margin was 42.6%, down 1.5 points from a year earlier. Operating costs exceeded revenue by $47.6M, an operating margin of -26.3%. Operating expenses grew 32% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+1198%). The quarter ended with a net loss of $45.1M, wider than the previous quarter's $25.9M loss.
Operating cash flow was $20.3M (up 46% year over year). Non-cash charges added back $17.3M of depreciation and amortization and $12.2M of share-based compensation. Working capital and other items added $35.9M. Capital expenditures of $6.3M left free cash flow of $14.0M.
Questions
What was Neogenomics' revenue in the second quarter 2025?
Neogenomics (NEO) reported revenue of $181M for the second quarter 2025 (Q2 2025), +10% from a year earlier and +8% from the quarter before.
Was Neogenomics profitable in the second quarter 2025?
Operating loss was $47.6M (-26.3% of revenue) and net loss $45.1M.
Source: Neogenomics 10-Q on SEC EDGAR.